Most children with SARS-CoV-2–associated multisystem inflammatory syndrome (MIS-C) responded well to initial treatment and recovered.
A new hyperinflammatory illness associated with SARS-CoV-2 infections was recognized in the spring of 2020. Patients with this multisystem inflammatory syndrome (MIS-C) presented with myocarditis, hypotension, and inflammation. Investigators from one health system in New York City treated and followed children with MIS-C to determine the medium-term impact on their health.
From April to December 2020, 45 children were admitted with MIS-C and followed for a median of 6 months. On presentation, 76% required intensive care, 44% had signs of myocardial dysfunction, and 64% received vasopressors or inotropes for hypotension; inflammatory markers and cytokines were elevated in most children. The median length of stay was 5 days (range, 2–32 days).…
Reviewing Author
DisclosuresGrant/Research SupportNIH Institutional Clinical and Translational Science Award; Agency for Healthcare Research and Quality National Center for Pediatric Practice Based Research Learning; Patient-Centered Outcomes Research Institute
Editorial BoardsCurrent Problems in Pediatric Adolescent Healthcare
Leadership Positions in Professional Societies College of Physicians of Philadelphia (Board of Trustees)
DisclosuresGrant/Research SupportNIH Institutional Clinical and Translational Science Award; Agency for Healthcare Research and Quality National Center for Pediatric Practice Based Research Learning; Patient-Centered Outcomes Research Institute
Editorial BoardsCurrent Problems in Pediatric Adolescent Healthcare
Leadership Positions in Professional Societies College of Physicians of Philadelphia (Board of Trustees)